
    
      Up to 60 eligible participants will be randomized in a 1:1 ratio to receive either SAB-176
      (up to 50 mg/kg dose) or placebo. Healthy adult participants will be pre-screened for
      serosuitability for Influenza A/California/2009 H1N1 challenge virus. Serosuitable
      participants who sign the study specific informed consent form (ICF) will be challenged with
      an intranasal administration of Influenza A/California/2009 H1N1 virus on Day 0. Participants
      will be given intravenous (IV) infusion of SAB-176 or placebo on Day 1. Participants will be
      held in quarantine until Day 8.
    
  